Long-term corticosteroid treatment in giant cell arteritis

Area of Science:

• Rheumatology
• Internal Medicine
• Clinical Pharmacology

Background:

• Giant cell arteritis (GCA) is a systemic vasculitis often requiring prolonged corticosteroid treatment.
• Long-term corticosteroid use is associated with significant side effects and management challenges.

Purpose of the Study:

• To evaluate the long-term outcomes of corticosteroid therapy in patients with giant cell arteritis.
• To assess relapse rates and complications associated with prolonged steroid use in GCA.

Main Methods:

• A retrospective follow-up study of 90 patients diagnosed with giant cell arteritis.
• Analysis of patient data regarding duration of corticosteroid therapy, dosage, relapse frequency, and morbidity over 9-16 years.

Main Results:

• The mean duration of corticosteroid therapy was 5.8 years, with 43% of patients still on treatment at 5 years and 25% at 9 years (median dose 5 mg prednisolone).
• A 50% relapse rate was observed upon treatment withdrawal, with most relapses occurring within one year of cessation.
• No increased morbidity compared to the general population or significant steroid-related complications were identified.

Conclusions:

• Prolonged corticosteroid therapy is frequently required for giant cell arteritis, with a high rate of relapses upon treatment withdrawal.
• Despite long-term use, significant steroid-related complications and increased morbidity were not observed in this patient cohort.